<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436357</url>
  </required_header>
  <id_info>
    <org_study_id>10-0069</org_study_id>
    <nct_id>NCT01436357</nct_id>
  </id_info>
  <brief_title>Staged Phase I/II Hepatitis C Prophylactic Vaccine</brief_title>
  <official_title>A Staged Phase I/II Study, to Assess Safety, Efficacy and Immunogenicity of a New Hepatitis C Prophylactic Vaccine Based on Sequential Use of AdCh3NSmut1 and MVA-NSmut</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two stage, phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C
      virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45. AdCh3NSmut1
      and MVA-NSMut HCV vaccine will be administered to 68 (+/-4) volunteers in stage 1. A planned
      interim analysis of safety and immunogenicity will be conducted. If no safety signal is
      detected and there is evidence of a measurable immune response to HCV then 472 (+/-4)
      volunteers will be enrolled in stage 2. Primary objectives are to 1) assess the safety of
      AdCh3NSmut1 and MVA-NSmut compared to placebo when administered to HCV-uninfected IDUs and 2)
      determine if AdCh3NSmut1 and MVA-NSmut HCV vaccines will reduce incidence of chronic HCV
      infection compared to placebo among HCV-uninfected IDUs. Planned study duration is approx 63
      months (accrual time, 2 months vaccination, 18 months follow-up, and 9 months extended
      observation for subjects becoming viremic in the last month of follow-up).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two stage, phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C
      virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45. In this
      clinical trial AdCh3NSmut1 and MVA-NSMut HCV vaccine will be administered intramuscularly to
      68 (+/-4) evaluable volunteers in stage 1. A planned interim analysis of safety and
      immunogenicity will be conducted based on data through 1 week after receipt of the second
      vaccination. If no safety signal is detected and there is evidence of a measurable immune
      response to HCV then an additional 472 (+/-4) volunteers will be enrolled in stage 2. The
      primary objectives of this study will be 1) to assess the safety of the new candidate
      hepatitis C virus vaccines, AdCh3NSmut1 and MVA-NSmut, compared to placebo when administered
      to HCV-uninfected injection drug users (IDUs) and 2) to determine if AdCh3NSmut1 and
      MVA-NSmut HCV vaccines will reduce incidence of chronic HCV infection compared to placebo
      among HCV-uninfected IDUs. The secondary objective of this study will be to evaluate the
      immunogenicity of the new candidate hepatitis C virus vaccines, AdCh3NSmut1 and MVA-NSmut,
      compared to placebo when administered to HCV-uninfected IDUs.The planned duration of the
      study is approximately 63 months total including accrual time for subjects (assuming 31
      months of screening/enrollments, plus 3 months of halted enrollment for the first interim
      analysis), 2 months vaccination, 18 months follow-up of each enrolled subject, and 9 months
      extended observation (monthly), from the time of infection, for subjects becoming viremic in
      the last month of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 6, 2012</start_date>
  <completion_date type="Anticipated">July 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of chronic hepatitis C virus (HCV) infection at 6 months defined by persistent viremia over a period of 6 months after initial detection of primary infection.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinical safety laboratory adverse events (AEs) assessed at baseline and 1 month following each vaccination, per treatment arm.</measure>
    <time_frame>Day 0 to 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of severe local and/or systemic solicited reactogenicity signs and symptoms in the 8 days (Day 0-7) after each vaccination, per treatment arm.</measure>
    <time_frame>Day 0 to 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of vaccine-related serious adverse events (SAEs) from the time of first vaccination through the entire study period, per treatment arm.</measure>
    <time_frame>Day 0 to 29 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of positive cell mediated immune response by treatment group (vaccine vs. placebo) measured by interferon gamma (IFN-gamma) production by T-cells in response to at least one out of the six HCV genotype 1b peptide pools in the vaccine.</measure>
    <time_frame>Within 14 days after the last vaccination (Day 56)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">548</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm A (Stage I and II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Stage I and II)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh3NSmut1</intervention_name>
    <description>Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose, intramuscularly on day 0.</description>
    <arm_group_label>Arm A (Stage I and II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-NSmut</intervention_name>
    <description>Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10^8 plaque forming units (pfu) intramuscularly on day 56.</description>
    <arm_group_label>Arm A (Stage I and II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.</description>
    <arm_group_label>Arm B (Stage I and II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Comprehension of informed consent. - 18-45 year old men or women with acknowledged active
        IDU in the past 90 days and have no travel plans that would interfere with ability to meet
        the study visit schedule. - In good general health as determined by a participating study
        physician and results within acceptable ranges for clinical laboratory evaluations as
        detailed in Appendix A. - Negative for antibodies to hepatitis C virus (anti-HCV). -
        Negative for HCV RNA. - Negative antibodies to HIV. - Negative for HBsAg. - Able and
        willing (in the Investigator's opinion) to comply with all study requirements. - Willing to
        allow the investigators access to their medical records. - Willingness to practice
        continuous effective contraception from the screening visit through 90 days after the last
        vaccination (males and females). - Among females, a negative pregnancy test within 24 hours
        prior to vaccination. - Agreement to refrain from blood donation during the course of the
        study or after the study. - Provide written informed consent prior to initiation of any
        study procedures. - Willing to provide contact information for study follow-up activities,
        including the address, name and contact information of three people who can be contacted to
        facilitate follow-up compliance.

        Exclusion Criteria:

        - The subject is currently participating in a study that involves an experimental agent
        (vaccine, drug, biologic device, blood product, or medication) or has received an
        experimental agent within 30 days prior to enrollment in this study, or expects to receive
        another experimental agent during participation in this study. - Prior receipt of a
        recombinant simian or human adenoviral vaccine or MVA vaccine. - Administration of
        immunoglobulins and/or any blood products within the 90 days preceding the planned
        administration of the vaccine candidate. - Any confirmed or suspected immunosuppressive or
        immunodeficient state, including: HIV infection; asplenia; recurrent, severe infections. -
        History of allergic disease or reactions likely to be exacerbated by any component of the
        vaccine (i.e., known hypersensitivity to aminoglycosideantibiotics or to egg proteins). -
        History of clinically significant contact dermatitis or other significant dermatological
        conditions such as psoriasis. - Any history of anaphylaxis in reaction to vaccination. -
        Pregnancy, lactation or willingness/intention to become pregnant during the study. -
        History of cancer (except for successfully treated basal cell carcinoma of the skin and
        cervical carcinoma in situ). - History of severe psychiatric illness, including severe
        depression, history of suicidal ideation, suicidal attempts, or psychosis requiring
        medication. The subject has a diagnosis of schizophrenia, bi-polar disease, or other severe
        (disabling) chronic psychiatric diagnosis that is uncontrolled and would interfere with the
        ability to adhere to the protocol. - Any other serious chronic illness requiring hospital
        specialist supervision. - Suspected or known current alcohol abuse as defined by a score of
        10 or more on the Alcohol Use Disorders Identification Test (AUDIT) C test (a standardized
        screening tool used to identify hazardous drinkers or those with active alcohol use
        disorders, including abuse or dependence). - At high risk of HIV infection by the following
        criteria (adapted from HIV Network for Prevention Trials (HIVNET) behavioral criteria for
        high risk of HIV): (1) sexually active male who has sex with men (MSM), defined as (i) male
        who has had anal sex with male sexual partner or partners in the past year or (ii) a male
        who exchanged sex with male partner(s) for money or drugs in the past year; and (2) female
        and in a current relationship with a high risk male (active MSM, HIV positive male). - Any
        other significant disease, disorder or finding, which, in the opinion of the Investigator,
        may put the subject at risk because of participation in the study, may influence the result
        of the study, or may influence the subject's ability to participate in the study. - History
        of or current diagnosis of Diabetes mellitus. - History of or current diagnosis of
        autoimmune disease. - History of or current cardiac disease including history of myocardial
        infarction or arrhythmia. - Current diagnosis of active liver disease. - History of seizure
        disorder or currently taking anti-convulsant therapy that would interfere with safety
        evaluation. - Uncontrolled hypertension (defined as systolic blood pressure being greater
        than 140mm Hg or diastolic blood pressure being greater than 90mm Hg). - History of
        splenectomy. - Long term immunosuppressive use (defined as taken for 14 days or more in
        total at any time during the past 180 days) of high dose oral or parenteral glucocorticoids
        (high dose defined as prednisone &gt;/=20 mg total daily dose, or equivalent dose of other
        glucocorticoids); or high-dose inhaled steroids (high dose defined as &gt;800 mcg/day of
        beclomethasone dipropionate or equ ivalent); or any use of hepatotoxic or non-FDA approved
        medication. - Have an acute illness, including an oral temperature greater than or equal to
        100.4 degrees Fahrenheit, within 7 days prior to the first vaccination. - Immunization
        against another pathogen within 14 days of planned injection. Second vaccination exclusion
        criteria: The following events associated with vaccine immunization constitute absolute
        contraindications to further administration of vaccine. The subject will not receive
        additional vaccination, but will continue with scheduled follow-up procedures except
        vaccination. 1. Anaphylactic reaction following administration of vaccine. 2. Pregnancy. If
        a woman reports having a positive home urine pregnancy test or a positive in clinic urine
        pregnancy test prior to a scheduled second vaccination, she is not eligible to receive the
        study vaccine. If she later returns to clinic and reports having a negative home urine
        pregnancy test and this is confirmed by a negative in clinic urine pregnancy test and a
        negative blood pregnancy test she may be eligible for the second vaccination if she is
        still within the vaccination window and no other exclusion criteria are met. The following
        adverse events constitute contraindications to administration of vaccine at that point in
        time. If any one of these adverse events occurs at the time scheduled for vaccination, the
        subject may be vaccinated at a later date (within 28 days of scheduled administration) or
        withdrawn at the discretion of the investigator. The subject will not receive additional
        vaccination, but will continue with all scheduled follow-up procedures except vaccination.
        3. Acute disease at the time of vaccination (acute disease is defined as the presence of a
        moderate or severe illness with or without fever). The vaccine dose can be administered to
        persons with a minor illness such as diarrhea, mild upper respiratory infection with or
        without low-grade febrile illness, i.e., temperature of &lt;38째C (100.4째F). 4. Temperature of
        &gt;38째C (100.4째F) at the time of vaccination. 5. Immunization against another pathogen within
        14 days of vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California San Francisco - Tenderloin Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102-4012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Community Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General Hospital Unit 5B</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Public Health - Wood Clinic</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205-2400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico - Truman Health Services</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 5, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AdCh3NSmut1</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>MVA-NSmut</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

